- CEACAM1 antibodies for anti-viral therapy: immune response against viruses is specific and allows an application to a broad range of viruses.
- Technology Benefits
- Complementary anti-viral therapy Option
Applies to a broad range of viruses
Specific immune response against specific viruses
- Technology Application
- therapeutic development
- Detailed Technology Description
- The approach is based on a antibody-mediated stimulation of the carcino-embryonic antigen-related cell adhesion molecule 1 (CEACAM1), which activates early parts of both the B cell and T cell receptor-induced signal transduction. The researchers have shown on the example of the lymphocytic choriomeningitis virus (LCMV) that these antibodies stimulate the activation and expansion of virus specific cytotoxic T cells, which comes along with a reduced virus load in serum and organs of mice. In vitro studies confirmed efficacy also against influenza virus and cytomegalovirus.
- Type of Cooperation
- Application Date
- Application No.
- US201615221612 20160728
- - international:
A61K38/177; A61K39/095; A61K39/102; A61K39/1045; C07K16/2803; C12N5/0638; C07K2317/24; C07K2317/565; C07K2317/75; C07K2317/76; C07K2317/92; C07K2319/30; C12N2501/58; Y02A50/466
- Patent application
- ID No.
For more information, please click Here